查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1140204

核酸疗法市场：按产品分类（反义寡核甘酸和 DNA 适体、RNA 干扰和短干扰 RNA 等）、按应用分类、按最终用户分类：2021-2031 年全球机会分析和行业预测

Nucleic Acid Therapeutics Market By Products (Anti-Sense Oligonucleotides and DNA Aptamers, RNA Interference and Short Interfering RNAs, Others), By Application, By End User: Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 | 商品交期: 2-3个工作天内

价格

核酸是携带细胞遗传信息的化学物质。

核酸分为三种类型：脱氧核糖核酸 (DNA)、核糖核酸 (RNA) 和人工核酸。 Watson-Crick 碱基配对以序列特异性方式识别内源性核酸，并介导所有核酸共有的作用机制。基于核酸的疗法被广泛用于治疗多种慢性疾病。核酸在癌症、肿瘤、糖尿病、肺结核和人类免疫缺陷病毒 (HIV) 等慢性疾病中显示出巨大的治疗益处。例如，近年来，世界核酸治疗受到了极大的关注。此外，慢性病的增加和慢性病治疗方法的探索是国际关注的问题，核酸治疗越来越受到关注。

核酸疗法通过基因编辑、基因抑制、基因添加和基因替换发挥长期作用。此外，慢性病患病率的增加和寻求核酸治疗的患者数量的增加正在帮助全球核酸治疗市场的增长。核酸疗法显示出长期的治愈效果。推动全球核酸治疗市场增长的主要因素是慢性病患病率的增加和新型核酸治疗药物的不断发展。高昂的研发成本和昂贵的治疗和技术是製约市场增长的一些主要因素。核酸治疗药物开发的高产品需求和製药公司日益集中是推动核酸治疗市场增长的额外因素。癌症、肌营养不良症和人类免疫缺陷病毒 (HIV) 缺乏治疗选择是全球核酸治疗市场扩大的关键原因。核酸治疗市场审查批准用反义寡核甘酸治疗淀粉样变性以降低转甲状腺素蛋白 (TTR) 水平和 ISTH0036 在青光眼患者接受小梁切除术的安全性将通过剂量扩大进行改进例如，有多种疗法正在筹备中，有望满足全球对核酸疗法的需求，并有助于市场的增长。

核酸疗法根据产品、应用、最终用户和地理位置进行细分。根据产品，市场分为反义寡核甘酸（ASOS）和DNA适体、RNA干扰[RNAi]和短干扰RNA[siRNA]等。还有一些被归类为拮抗剂、RNA海绵和锁定核酸。通过应用，市场分为单基因和多基因疾病。最终用户分为医院/诊所和学术/研究机构。

内容

第一章介绍

第 2 章执行摘要

第 3 章市场概览

  • 市场定义和范围
  • 主要发现
    • 主要投资领域
  • 波特五力分析
  • 主要公司的定位
  • 市场动态
    • 驱动程序
    • 约束因素
    • 机会
  • COVID-19 影响分析

第 4 章核酸疗法市场：按产品分类

  • 概览
    • 市场规模和预测
  • 反义寡核甘酸 (ASO) 和 DNA 适体
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • RNA 干扰 [RNAi]、短干扰 RNA [siRNA]
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 其他
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 5 章核酸疗法市场：按应用分类

  • 概览
    • 市场规模和预测
  • 单一疾病
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 多基因疾病
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 6 章核酸疗法市场：按最终用户分类

  • 概览
    • 市场规模和预测
  • 医院和诊所
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 学术和研究机构
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 7 章核酸疗法市场：按地区划分

  • 概览
    • 市场规模和预测
  • 北美
    • 主要趋势和机遇
    • 北美市场规模和预测：按产品分类
    • 北美市场规模和预测：按应用
    • 北美市场规模和预测：按最终用户分类
    • 北美市场规模和预测：按国家/地区分类
      • 美国
      • 加拿大
      • 墨西哥
  • 欧洲
    • 主要趋势和机遇
    • 欧洲市场规模和预测：按产品分类
    • 欧洲市场规模和预测：按应用
    • 欧洲市场规模和预测：按最终用户分类
    • 欧洲市场规模和预测：按国家/地区分类
      • 德国
      • 法国
      • 英国
      • 意大利
      • 西班牙
      • 其他欧洲
  • 亚太地区
    • 主要趋势和机遇
    • 亚太市场规模和预测：按产品分类
    • 亚太市场规模和预测：按应用
    • 亚太市场规模和预测：按最终用户分类
    • 亚太地区的市场规模和预测：按国家/地区分类
      • 日本
      • 中国
      • 澳大利亚
      • 印度
      • 韩国
      • 其他亚太地区
  • LAMEA
    • 主要趋势和机遇
    • LAMEA 市场规模和预测：按产品分类
    • LAMEA 市场规模和预测：按应用
    • LAMEA 市场规模和预测：按最终用户分类
    • LAMEA 市场规模和预测：按国家/地区分类
      • 巴西
      • 沙特阿拉伯
      • 南非
      • LAMEA 的其余部分

第八章企业情况

  • 简介
  • 关键成功策略
  • 10 家主要公司的产品映射
  • 竞赛仪表板
  • 比赛热图
  • 主要发展

第 9 章公司简介

  • Agilent Technologies
  • Alnylam Pharmaceuticals
  • Arbutus Biopharma
  • Arrrowhead
  • Benitec Biopharma
  • Caperna
  • Copernicus
  • Genzyme Sanofi
  • Ionis Pharmaceuticals
  • Merck
  • Novartis A.G
  • PYC Therapeutics Limited
  • Protagonist Therapeutics
  • Qaigen NV
  • Sarpeta Therapeutics
  • Silence Therapeutics
  • Thermo Fisher Scientific
  • Wavelifesciences
Product Code: A17089

Nucleic acids are chemical substances and carry genetic information of the cell. The three types of nucleic acids are deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and artificial nucleic acid. Watson-Crick base pairing recognizes endogenous nucleic acids in a sequence-specific manner, mediating the shared mode of action of all nucleic acids. The nucleic acid-based therapies are widely used to treat various chronic diseases. Nucleic acid shows the significant therapeutic result in chronic diseases, such as cancer, tumor, diabetes, tuberculosis, and human immunodeficiency virus (HIV). For instance, in recent years, the global nucleic acid therapeutics has gained extensive attention. Moreover, the increasing chronic illnesses and the search for cure of chronic illnesses is an international concern, therefore nucleic acid therapeutics is observing increased attention.

The nucleic acid therapeutics shows long lasting effects through gene editing, gene inhibition, gene addition or gene replacement. Furthermore, the increase in chronic disease prevalence and patients seeking treatment of nucleic acid therapies help in the global nucleic acid therapeutics market growth. Nucleic acid therapeutics shows the long lasting and curative effects. The key drivers for the growth of the global nucleic acid therapeutics market are increasing chronic illness and immensely developing novel treatments of nucleic acids. The high cost of research and development and expensive treatments and technologies are some major elements restraining the market growth. High product demand and growing concentration of pharmaceutical companies on the development of treatment for nucleic acid therapeutics are additional factors that are driving the nucleic acid therapeutics market growth. The lack of treatment alternatives for cancer, muscular dystrophy, and human immunodeficiency virus (HIV) is the important reason for global nucleic acid therapeutics market expansion. The nucleic acid therapeutics market will revamp on approval of the developing therapies for amyloidosis by using antisense oligonucleotide to lower transthyretin (TTR) levels and dose escalation to investigate safety of ISTH0036 in glaucoma undergoing trabeculectomy patients. For instance, there are various therapies under pipeline, which are expected to serve the demand for  nucleic acid therapies globally and contribute to the market growth.

The nucleic acid therapeutics is segmented on the basis of products, application, end user, and region. Based on the products, the market is bifurcated into anti-sense oligonucleotides (ASOS) and DNA aptamers, RNA interference [RNAi] and short interfering RNAs [siRNAs], and others. The others segment is further classified into antagomir and RNA sponge and locked nucleic acid. By application, the market is fragmented into monogenetic disorders and multi-genetic disorders. By end user, the market is segmented into hospitals & clinics and academic & research institutes.

Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Major key players that operate in the global nucleic acid therapeutics market are Agilent Technologies Inc., Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Benetic Biopharma, Inc., Caperna Inc. [Moderna], Copernicus Therapeutics, Genzyme (Sanofi), Ionis Pharmaceuticals, MERCK KGAA, Novartis AG, Phylogica, Protagonist Therapeutics, QIAGEN N.V., Sarepta Therapeutics, Silence Therapeutics plc., and Thermo Fisher Scientific Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the nucleic acid therapeutics market analysis from 2021 to 2031 to identify the prevailing nucleic acid therapeutics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the nucleic acid therapeutics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global nucleic acid therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Products

  • Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers
  • RNA interference [RNAi] and short interfering RNAs [siRNAs]
  • Others

By Application 

  • Monogenetic disorders
  • Multi-genetic disorders

By End User

  • Hospitals and Clinics
  • Academic and Research Institutes

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Agilent Technologies
    • Alnylam Pharmaceuticals
    • Arbutus Biopharma
    • Arrrowhead
    • Benitec Biopharma
    • Caperna
    • Copernicus
    • Genzyme Sanofi
    • Ionis Pharmaceuticals
    • Merck
    • Novartis A.G
    • PYC Therapeutics Limited
    • Protagonist Therapeutics
    • Qaigen NV
    • Sarpeta Therapeutics
    • Silence Therapeutics
    • Thermo Fisher Scientific
    • Wavelifesciences

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 RNA interference [RNAi] and short interfering RNAs [siRNAs]
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Others
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country

CHAPTER 5: NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION 

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Monogenetic disorders
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Multi-genetic disorders
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country

CHAPTER 6: NUCLEIC ACID THERAPEUTICS MARKET, BY END USER

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospitals and Clinics
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Academic and Research Institutes
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country

CHAPTER 7: NUCLEIC ACID THERAPEUTICS MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Products
    • 7.2.3 North America Market size and forecast, by Application 
    • 7.2.4 North America Market size and forecast, by End User
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Products
      • 7.2.5.1.2 Market size and forecast, by Application 
      • 7.2.5.1.3 Market size and forecast, by End User
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Products
      • 7.2.5.2.2 Market size and forecast, by Application 
      • 7.2.5.2.3 Market size and forecast, by End User
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Products
      • 7.2.5.3.2 Market size and forecast, by Application 
      • 7.2.5.3.3 Market size and forecast, by End User
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Products
    • 7.3.3 Europe Market size and forecast, by Application 
    • 7.3.4 Europe Market size and forecast, by End User
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Products
      • 7.3.5.1.2 Market size and forecast, by Application 
      • 7.3.5.1.3 Market size and forecast, by End User
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Products
      • 7.3.5.2.2 Market size and forecast, by Application 
      • 7.3.5.2.3 Market size and forecast, by End User
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Products
      • 7.3.5.3.2 Market size and forecast, by Application 
      • 7.3.5.3.3 Market size and forecast, by End User
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Products
      • 7.3.5.4.2 Market size and forecast, by Application 
      • 7.3.5.4.3 Market size and forecast, by End User
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Products
      • 7.3.5.5.2 Market size and forecast, by Application 
      • 7.3.5.5.3 Market size and forecast, by End User
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Products
      • 7.3.5.6.2 Market size and forecast, by Application 
      • 7.3.5.6.3 Market size and forecast, by End User
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Products
    • 7.4.3 Asia-Pacific Market size and forecast, by Application 
    • 7.4.4 Asia-Pacific Market size and forecast, by End User
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Products
      • 7.4.5.1.2 Market size and forecast, by Application 
      • 7.4.5.1.3 Market size and forecast, by End User
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Products
      • 7.4.5.2.2 Market size and forecast, by Application 
      • 7.4.5.2.3 Market size and forecast, by End User
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Market size and forecast, by Products
      • 7.4.5.3.2 Market size and forecast, by Application 
      • 7.4.5.3.3 Market size and forecast, by End User
      • 7.4.5.4 India
      • 7.4.5.4.1 Market size and forecast, by Products
      • 7.4.5.4.2 Market size and forecast, by Application 
      • 7.4.5.4.3 Market size and forecast, by End User
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Products
      • 7.4.5.5.2 Market size and forecast, by Application 
      • 7.4.5.5.3 Market size and forecast, by End User
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Products
      • 7.4.5.6.2 Market size and forecast, by Application 
      • 7.4.5.6.3 Market size and forecast, by End User
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Products
    • 7.5.3 LAMEA Market size and forecast, by Application 
    • 7.5.4 LAMEA Market size and forecast, by End User
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Products
      • 7.5.5.1.2 Market size and forecast, by Application 
      • 7.5.5.1.3 Market size and forecast, by End User
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Products
      • 7.5.5.2.2 Market size and forecast, by Application 
      • 7.5.5.2.3 Market size and forecast, by End User
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Products
      • 7.5.5.3.2 Market size and forecast, by Application 
      • 7.5.5.3.3 Market size and forecast, by End User
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Products
      • 7.5.5.4.2 Market size and forecast, by Application 
      • 7.5.5.4.3 Market size and forecast, by End User

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Agilent Technologies
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Alnylam Pharmaceuticals
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Arbutus Biopharma
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Arrrowhead
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Benitec Biopharma
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Caperna
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Copernicus
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Genzyme Sanofi
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Ionis Pharmaceuticals
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Merck
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments
  • 9.11 Novartis A.G
    • 9.11.1 Company overview
    • 9.11.2 Company snapshot
    • 9.11.3 Operating business segments
    • 9.11.4 Product portfolio
    • 9.11.5 Business performance
    • 9.11.6 Key strategic moves and developments
  • 9.12 PYC Therapeutics Limited
    • 9.12.1 Company overview
    • 9.12.2 Company snapshot
    • 9.12.3 Operating business segments
    • 9.12.4 Product portfolio
    • 9.12.5 Business performance
    • 9.12.6 Key strategic moves and developments
  • 9.13 Protagonist Therapeutics
    • 9.13.1 Company overview
    • 9.13.2 Company snapshot
    • 9.13.3 Operating business segments
    • 9.13.4 Product portfolio
    • 9.13.5 Business performance
    • 9.13.6 Key strategic moves and developments
  • 9.14 Qaigen NV
    • 9.14.1 Company overview
    • 9.14.2 Company snapshot
    • 9.14.3 Operating business segments
    • 9.14.4 Product portfolio
    • 9.14.5 Business performance
    • 9.14.6 Key strategic moves and developments
  • 9.15 Sarpeta Therapeutics
    • 9.15.1 Company overview
    • 9.15.2 Company snapshot
    • 9.15.3 Operating business segments
    • 9.15.4 Product portfolio
    • 9.15.5 Business performance
    • 9.15.6 Key strategic moves and developments
  • 9.16 Silence Therapeutics
    • 9.16.1 Company overview
    • 9.16.2 Company snapshot
    • 9.16.3 Operating business segments
    • 9.16.4 Product portfolio
    • 9.16.5 Business performance
    • 9.16.6 Key strategic moves and developments
  • 9.17 Thermo Fisher Scientific
    • 9.17.1 Company overview
    • 9.17.2 Company snapshot
    • 9.17.3 Operating business segments
    • 9.17.4 Product portfolio
    • 9.17.5 Business performance
    • 9.17.6 Key strategic moves and developments
  • 9.18 Wavelifesciences
    • 9.18.1 Company overview
    • 9.18.2 Company snapshot
    • 9.18.3 Operating business segments
    • 9.18.4 Product portfolio
    • 9.18.5 Business performance
    • 9.18.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 2. NUCLEIC ACID THERAPEUTICS MARKET SIZE, FOR ANTI-SENSE OLIGONUCLEOTIDES (ASOS) AND DNA APTAMERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. NUCLEIC ACID THERAPEUTICS MARKET FOR ANTI-SENSE OLIGONUCLEOTIDES (ASOS) AND DNA APTAMERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. NUCLEIC ACID THERAPEUTICS MARKET SIZE, FOR RNA INTERFERENCE [RNAI] AND SHORT INTERFERING RNAS [SIRNAS], BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. NUCLEIC ACID THERAPEUTICS MARKET FOR RNA INTERFERENCE [RNAI] AND SHORT INTERFERING RNAS [SIRNAS], BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. NUCLEIC ACID THERAPEUTICS MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. NUCLEIC ACID THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 8. GLOBAL NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 9. NUCLEIC ACID THERAPEUTICS MARKET SIZE, FOR MONOGENETIC DISORDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. NUCLEIC ACID THERAPEUTICS MARKET FOR MONOGENETIC DISORDERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 11. NUCLEIC ACID THERAPEUTICS MARKET SIZE, FOR MULTI-GENETIC DISORDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. NUCLEIC ACID THERAPEUTICS MARKET FOR MULTI-GENETIC DISORDERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 13. GLOBAL NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 14. NUCLEIC ACID THERAPEUTICS MARKET SIZE, FOR HOSPITALS AND CLINICS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. NUCLEIC ACID THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 16. NUCLEIC ACID THERAPEUTICS MARKET SIZE, FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 17. NUCLEIC ACID THERAPEUTICS MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 18. NUCLEIC ACID THERAPEUTICS MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 19. NORTH AMERICA NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 20. NORTH AMERICA NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 21. NORTH AMERICA NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 22. NORTH AMERICA NUCLEIC ACID THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 23. U.S. NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 24. U.S. NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 25. U.S. NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 26. CANADA NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 27. CANADA NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 28. CANADA NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 29. MEXICO NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 30. MEXICO NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 31. MEXICO NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 32. EUROPE NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 33. EUROPE NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 34. EUROPE NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 35. EUROPE NUCLEIC ACID THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 36. GERMANY NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 37. GERMANY NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 38. GERMANY NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 39. FRANCE NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 40. FRANCE NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 41. FRANCE NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 42. UK NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 43. UK NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 44. UK NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 45. ITALY NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 46. ITALY NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 47. ITALY NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 48. SPAIN NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 49. SPAIN NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 50. SPAIN NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 51. REST OF EUROPE NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 52. REST OF EUROPE NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 53. REST OF EUROPE NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 54. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 55. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 56. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 57. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 58. JAPAN NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 59. JAPAN NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 60. JAPAN NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 61. CHINA NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 62. CHINA NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 63. CHINA NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 64. AUSTRALIA NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 65. AUSTRALIA NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 66. AUSTRALIA NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 67. INDIA NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 68. INDIA NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 69. INDIA NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 70. SOUTH KOREA NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 71. SOUTH KOREA NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 72. SOUTH KOREA NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 73. REST OF ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 74. REST OF ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 75. REST OF ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 76. LAMEA NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 77. LAMEA NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 78. LAMEA NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 79. LAMEA NUCLEIC ACID THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 80. BRAZIL NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 81. BRAZIL NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 82. BRAZIL NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 83. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 84. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 85. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 86. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 87. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 88. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 89. REST OF LAMEA NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 90. REST OF LAMEA NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 91. REST OF LAMEA NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 92.AGILENT TECHNOLOGIES: COMPANY SNAPSHOT
  • TABLE 93.AGILENT TECHNOLOGIES: OPERATING SEGMENTS
  • TABLE 94.AGILENT TECHNOLOGIES: PRODUCT PORTFOLIO
  • TABLE 95.AGILENT TECHNOLOGIES: NET SALES,
  • TABLE 96.AGILENT TECHNOLOGIES: KEY STRATERGIES
  • TABLE 97.ALNYLAM PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 98.ALNYLAM PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 99.ALNYLAM PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 100.ALNYLAM PHARMACEUTICALS: NET SALES,
  • TABLE 101.ALNYLAM PHARMACEUTICALS: KEY STRATERGIES
  • TABLE 102.ARBUTUS BIOPHARMA: COMPANY SNAPSHOT
  • TABLE 103.ARBUTUS BIOPHARMA: OPERATING SEGMENTS
  • TABLE 104.ARBUTUS BIOPHARMA: PRODUCT PORTFOLIO
  • TABLE 105.ARBUTUS BIOPHARMA: NET SALES,
  • TABLE 106.ARBUTUS BIOPHARMA: KEY STRATERGIES
  • TABLE 107.ARRROWHEAD: COMPANY SNAPSHOT
  • TABLE 108.ARRROWHEAD: OPERATING SEGMENTS
  • TABLE 109.ARRROWHEAD: PRODUCT PORTFOLIO
  • TABLE 110.ARRROWHEAD: NET SALES,
  • TABLE 111.ARRROWHEAD: KEY STRATERGIES
  • TABLE 112.BENITEC BIOPHARMA: COMPANY SNAPSHOT
  • TABLE 113.BENITEC BIOPHARMA: OPERATING SEGMENTS
  • TABLE 114.BENITEC BIOPHARMA: PRODUCT PORTFOLIO
  • TABLE 115.BENITEC BIOPHARMA: NET SALES,
  • TABLE 116.BENITEC BIOPHARMA: KEY STRATERGIES
  • TABLE 117.CAPERNA: COMPANY SNAPSHOT
  • TABLE 118.CAPERNA: OPERATING SEGMENTS
  • TABLE 119.CAPERNA: PRODUCT PORTFOLIO
  • TABLE 120.CAPERNA: NET SALES,
  • TABLE 121.CAPERNA: KEY STRATERGIES
  • TABLE 122.COPERNICUS: COMPANY SNAPSHOT
  • TABLE 123.COPERNICUS: OPERATING SEGMENTS
  • TABLE 124.COPERNICUS: PRODUCT PORTFOLIO
  • TABLE 125.COPERNICUS: NET SALES,
  • TABLE 126.COPERNICUS: KEY STRATERGIES
  • TABLE 127.GENZYME SANOFI: COMPANY SNAPSHOT
  • TABLE 128.GENZYME SANOFI: OPERATING SEGMENTS
  • TABLE 129.GENZYME SANOFI: PRODUCT PORTFOLIO
  • TABLE 130.GENZYME SANOFI: NET SALES,
  • TABLE 131.GENZYME SANOFI: KEY STRATERGIES
  • TABLE 132.IONIS PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 133.IONIS PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 134.IONIS PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 135.IONIS PHARMACEUTICALS: NET SALES,
  • TABLE 136.IONIS PHARMACEUTICALS: KEY STRATERGIES
  • TABLE 137.MERCK: COMPANY SNAPSHOT
  • TABLE 138.MERCK: OPERATING SEGMENTS
  • TABLE 139.MERCK: PRODUCT PORTFOLIO
  • TABLE 140.MERCK: NET SALES,
  • TABLE 141.MERCK: KEY STRATERGIES
  • TABLE 142.NOVARTIS A.G: COMPANY SNAPSHOT
  • TABLE 143.NOVARTIS A.G: OPERATING SEGMENTS
  • TABLE 144.NOVARTIS A.G: PRODUCT PORTFOLIO
  • TABLE 145.NOVARTIS A.G: NET SALES,
  • TABLE 146.NOVARTIS A.G: KEY STRATERGIES
  • TABLE 147.PYC THERAPEUTICS LIMITED: COMPANY SNAPSHOT
  • TABLE 148.PYC THERAPEUTICS LIMITED: OPERATING SEGMENTS
  • TABLE 149.PYC THERAPEUTICS LIMITED: PRODUCT PORTFOLIO
  • TABLE 150.PYC THERAPEUTICS LIMITED: NET SALES,
  • TABLE 151.PYC THERAPEUTICS LIMITED: KEY STRATERGIES
  • TABLE 152.PROTAGONIST THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 153.PROTAGONIST THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 154.PROTAGONIST THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 155.PROTAGONIST THERAPEUTICS: NET SALES,
  • TABLE 156.PROTAGONIST THERAPEUTICS: KEY STRATERGIES
  • TABLE 157.QAIGEN NV: COMPANY SNAPSHOT
  • TABLE 158.QAIGEN NV: OPERATING SEGMENTS
  • TABLE 159.QAIGEN NV: PRODUCT PORTFOLIO
  • TABLE 160.QAIGEN NV: NET SALES,
  • TABLE 161.QAIGEN NV: KEY STRATERGIES
  • TABLE 162.SARPETA THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 163.SARPETA THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 164.SARPETA THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 165.SARPETA THERAPEUTICS: NET SALES,
  • TABLE 166.SARPETA THERAPEUTICS: KEY STRATERGIES
  • TABLE 167.SILENCE THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 168.SILENCE THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 169.SILENCE THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 170.SILENCE THERAPEUTICS: NET SALES,
  • TABLE 171.SILENCE THERAPEUTICS: KEY STRATERGIES
  • TABLE 172.THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
  • TABLE 173.THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
  • TABLE 174.THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
  • TABLE 175.THERMO FISHER SCIENTIFIC: NET SALES,
  • TABLE 176.THERMO FISHER SCIENTIFIC: KEY STRATERGIES
  • TABLE 177.WAVELIFESCIENCES: COMPANY SNAPSHOT
  • TABLE 178.WAVELIFESCIENCES: OPERATING SEGMENTS
  • TABLE 179.WAVELIFESCIENCES: PRODUCT PORTFOLIO
  • TABLE 180.WAVELIFESCIENCES: NET SALES,
  • TABLE 181.WAVELIFESCIENCES: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.NUCLEIC ACID THERAPEUTICS MARKET SEGMENTATION
  • FIGURE 2.NUCLEIC ACID THERAPEUTICS MARKET,2021-2031
  • FIGURE 3.NUCLEIC ACID THERAPEUTICS MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.NUCLEIC ACID THERAPEUTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.NUCLEIC ACID THERAPEUTICS MARKET,BY PRODUCTS,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ANTI-SENSE OLIGONUCLEOTIDES (ASOS) AND DNA APTAMERS NUCLEIC ACID THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF RNA INTERFERENCE [RNAI] AND SHORT INTERFERING RNAS [SIRNAS] NUCLEIC ACID THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF OTHERS NUCLEIC ACID THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 16.NUCLEIC ACID THERAPEUTICS MARKET,BY APPLICATION ,2021(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF MONOGENETIC DISORDERS NUCLEIC ACID THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF MULTI-GENETIC DISORDERS NUCLEIC ACID THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 19.NUCLEIC ACID THERAPEUTICS MARKET,BY END USER,2021(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF HOSPITALS AND CLINICS NUCLEIC ACID THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF ACADEMIC AND RESEARCH INSTITUTES NUCLEIC ACID THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 22.NUCLEIC ACID THERAPEUTICS MARKET BY REGION,2021
  • FIGURE 23.U.S. NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 24.CANADA NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 25.MEXICO NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 26.GERMANY NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 27.FRANCE NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 28.UK NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 29.ITALY NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 30.SPAIN NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 31.REST OF EUROPE NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 32.JAPAN NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 33.CHINA NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 34.AUSTRALIA NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 35.INDIA NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 36.SOUTH KOREA NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 37.REST OF ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 38.BRAZIL NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 39.SAUDI ARABIA NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 40.SOUTH AFRICA NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 41.REST OF LAMEA NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46.COMPETITIVE DASHBOARD
  • FIGURE 47.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 48.AGILENT TECHNOLOGIES.: NET SALES ,($MILLION)
  • FIGURE 49.ALNYLAM PHARMACEUTICALS.: NET SALES ,($MILLION)
  • FIGURE 50.ARBUTUS BIOPHARMA.: NET SALES ,($MILLION)
  • FIGURE 51.ARRROWHEAD.: NET SALES ,($MILLION)
  • FIGURE 52.BENITEC BIOPHARMA.: NET SALES ,($MILLION)
  • FIGURE 53.CAPERNA.: NET SALES ,($MILLION)
  • FIGURE 54.COPERNICUS.: NET SALES ,($MILLION)
  • FIGURE 55.GENZYME SANOFI.: NET SALES ,($MILLION)
  • FIGURE 56.IONIS PHARMACEUTICALS.: NET SALES ,($MILLION)
  • FIGURE 57.MERCK.: NET SALES ,($MILLION)
  • FIGURE 58.NOVARTIS A.G.: NET SALES ,($MILLION)
  • FIGURE 59.PYC THERAPEUTICS LIMITED.: NET SALES ,($MILLION)
  • FIGURE 60.PROTAGONIST THERAPEUTICS.: NET SALES ,($MILLION)
  • FIGURE 61.QAIGEN NV.: NET SALES ,($MILLION)
  • FIGURE 62.SARPETA THERAPEUTICS.: NET SALES ,($MILLION)
  • FIGURE 63.SILENCE THERAPEUTICS.: NET SALES ,($MILLION)
  • FIGURE 64.THERMO FISHER SCIENTIFIC.: NET SALES ,($MILLION)
  • FIGURE 65.WAVELIFESCIENCES.: NET SALES ,($MILLION)